logo
logo
Paysign, Inc.

Paysign, Inc.

NASDAQ•PAYS
CEO: Mr. Mark R. Newcomer
セクター: Technology
業種: Software - Infrastructure
上場日: 2007-10-10
Paysign, Inc. provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card. The company markets its prepaid card solutions under the Paysign brand. Its primary market focus is on companies and municipalities that require a streamlined payment solution for rewards, rebates, payment assistance, and other payments to their customers, employees, agents, and others. The company was formerly known as 3PEA International, Inc. and changed its name to Paysign, Inc. in April 2019. Paysign, Inc. was incorporated in 1995 and is headquartered in Henderson, Nevada.
連絡先情報
2615 St. Rose Parkway, Henderson, NV, 89052, United States
702-453-2221
www.paysign.com
時価総額
$190.45M
PER (TTM)
25.1
41
配当利回り
--
52週高値
$8.88
52週安値
$1.80
52週レンジ
23%
順位24Top 10.8%
5.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$21.60M+41.56%
直近4四半期の推移

EPS

$0.04+50.19%
直近4四半期の推移

フリーCF

$4.57M-120.21%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Net Income Soars 153.3% Nine-month net income reached $6.189M USD, marking a substantial 153.3% improvement over prior year results ending September 30, 2025.
Pharma Revenue Drives Growth Pharma industry revenue increased $15.955M USD, growing 191.3% due to 39 new patient affordability programs launched recently.
Operations Income Jumps Income from operations improved $4.951M USD to $5.509M, reflecting an 888.7% increase for the nine months ended September 30, 2025.

リスク要因

Pending Litigation Uncertainties Company faces ongoing securities class actions and derivative lawsuits; adverse results may harm future business operations and financial standing.
Customer Concentration Risk Accounts receivable concentration risk exists; one pharma customer represented 14% of receivables as of September 30, 2025.
Operating Cash Flow Decreased Net cash provided by operating activities fell $4.274M USD to $4.360M for nine months due to working capital timing shifts.

見通し

2025 Investment Strategy Focus Plans for remainder of 2025 include investing additional funds in technology improvements, sales, marketing, and cybersecurity expansion efforts.
Gamma Acquisition Integration Final valuation of Gamma acquisition assets and liabilities will be completed within the one-year measurement period following the March 2025 closing.
Platform Expansion Continuing Continuing platform expansion by evaluating emerging technologies and engaging hardware/software vendors for infrastructure components development.

同業比較

売上高 (TTM)

Bakkt Holdings, Inc.BKKT
$3.85B
+102.0%
Rackspace Technology, Inc.RXT
$2.69B
-3.0%
Lesaka Technologies, Inc.LSAK
$743.30M
+21.1%

粗利益率 (最新四半期)

ReposiTrak, Inc.TRAK
85.7%
+1.5pp
Kaltura, Inc.KLTR
70.0%
+3.4pp
Rekor Systems, Inc.REKR
63.4%
+19.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
OCFT$8.60B-2.9-25.5%0.6%
LSAK$354.00M-6.3-19.5%2.2%
BKTI$304.59M23.337.1%1.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
11.4%
安定成長
4四半期純利益CAGR
17.3%
収益性の大幅な改善
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年3月24日
|
EPS:-
|
売上高:-
財務レポート
財務データ
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月13日|
    売上高: $21.60M+41.6%
    |
    EPS: $0.04+50.2%
    予想を上回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $19.08M+33.1%
    |
    EPS: $0.03+93.9%
    予想を下回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月9日|
    売上高: $18.60M+41.0%
    |
    EPS: $0.05+762.1%
    予想を上回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月26日|
    売上高: $58.38M+23.5%
    |
    EPS: $0.07-40.3%
    予想を上回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月6日|
    売上高: $15.26M+23.0%
    |
    EPS: $0.03+28.7%
    予想を上回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月1日|
    売上高: $14.33M+29.8%
    |
    EPS: $0.01-760.0%
    予想を上回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月8日|
    売上高: $13.19M+30.0%
    |
    EPS: $0.01-287.1%
    予想を下回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月27日|
    売上高: $47.27M+24.3%
    |
    EPS: $0.12+506.1%
    予想を上回る